Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vismodegib - Roche

Drug Profile

Vismodegib - Roche

Alternative Names: Erivedge; GDC-0449; R 3616; RG 3616

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curis
  • Developer Centre Hospitalier Univeristaire De Lille; Clinica Universidad de Navarra; Erasmus Hospital; Genentech; National Cancer Institute (USA); Roche; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Benzamides; Small molecules; Sulfones
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Basal cell nevus syndrome; Breast cancer; Chondrosarcoma; Gastric cancer; Medulloblastoma; Pancreatic cancer; Small cell lung cancer
  • Discontinued Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Glioblastoma; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Myelodysplastic syndromes; Myelofibrosis; Ovarian cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 01 Aug 2019 Genentech and the Bluestone Center for Clinical Research completes a phase II trial for Basal cell nevus syndrome in USA (PO) (NCT02366312)
  • 25 Mar 2019 Curis enters into into an agreement for vismodegib for funds managed by Oberland Capital
  • 07 Feb 2019 Discontinued - Phase-I/II for Graft-versus-host disease (Treatment-experienced) in USA (PO) (NCT02337517)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top